ReNeuron makes strong start to key trial period
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 13 of 15
Archive
Proactive news round-up: Amryt Pharma, Minds+Machines, Aminex ...
A glance at today's headlines on the Proactive newswire
Archive
WEEK AHEAD: The panto season is upon us, and lead villain Mike Ashley is due on stage
He's already told us he's not Santa, but can Mike Ashley deliver a Christmas present for Sports Direct investors?
Are ReNeuron shares ready to explode?
The drifting share price has bottomed out and now represents an “early bird opportunity”, according to Zak Mir
ReNeuron Group PLC's stem cell tech significantly undervalued
“ReNeuron remains well-funded to advance all of its therapeutic programmes through to further significant clinical milestones and we look forward to reporting further progress in the months ahead,” added Hellebø.
ReNeuron Group will hit "milestone" with results next year, says CEO
All patients have now been treated in the PISCES II Phase II clinical trial.
US markets close flat after London rate cut rally fizzles out
After mid-session high, market calms down by end of session
US stock market continues rally after BOE rate cut
Market sees positive activity following unexpected rate cut.
Proactive news highlights: Aminex, Aggregated Micro Power, Magnolia, Metminco and more...
Aggregated Micro Power raises £5mln to fund acquisitions, Metminco firms up terms of the farm-out and Aminex raises a further £1.3mln.
ReNeuron stroke results to be showcased in premier medical journal
We are delighted that the PISCES I clinical trial data has been published in such a prestigious peer reviewed medical journal as The Lancet - Chief executive Olav Hellebø.
Proactive news highlights - Ariana Resources, Cloudbuy, Ferrum Crescent, Kibo Mining and ReNeuron.
NetScientific will deploy its medical tech platform in multiple languages to accommodate multi-cultural clients, Ariana Resources is raising £445,000 to fund exploration drilling and Ferrum Crescent is advancing its Moonlight iron ore proje
ReNeuron unveils positive pre-clinical data from eye trial
The firm recently kicked off a phase I/II clinical trial in the USA and initial short-term safety and tolerability data from the phase I part in the first nine patients is expected in early 2017.
Brexit wrecks it again
FTSE100 shares ended lower on Monday, weighed down by mounting concerns over a possible “Brexit” of the UK from the European Union in a referendum later this month
Investments and investor services
Fitbug catches cold as FTSE 100 Index drops
The FTSE 100 Index fell 51 points to 6065 after the Shanghai Composite closed lower
Risers & Fallers: Ascent Resources, Onzima Ventures, Aveva Group, ReNeuron Group, Egdon Resources, Plutus Powergen
The merger between Aveva Group and Schneider could be back on
ReNeuron completes recruitment for phase II stroke trial
Three-month follow-up data is expected to be available in the fourth quarter of this year.
Proactive news highlights: Deltex, W Resources, Cloudtag and more…
Deltex sings up two new US accounts, W Resources unveils its maiden resource estimate for the São Martinho Gold Deposit, while Cloudtag gets some major retailers on board.
ReNeuron to tackle brain cancer with exosome candidate
Based on promising findings of pre-clinincal models, ReNeuron will be targeting the most common and aggressive form of brain cancer
ReNeuron clinical trial making progress
Researchers at Massachusetts Eye and Ear in Boston are using human retinal progenitor cells (hRPC) to possibly halt the progression of retinitis pigmentosa (RP).
Archive
Proactive news summary: Accesso technology group, Aminex PLC, Green Dragon Gas PLC and more
Horizonte Minerals and its game-changing deal, Chinese Green Dragon subsidy and hefty write-offs for troubled IPSA.